Citations (84)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Alexandrine Corriger & Gisèle Pickering. (2019) Ketamine and depression: a narrative review. Drug Design, Development and Therapy 13, pages 3051-3067.
Read now
Read now
Elodie Martin, Marc Sorel, Véronique Morel, Fabienne Marcaillou, Pascale Picard, Noémie Delage, Florence Tiberghien, Marie-Christine Crosmary, Mitra Najjar, Renato Colamarino, Christelle Créach, Béatrice Lietar, Géraldine Brumauld de Montgazon, Anne Margot-Duclot, Marie-Anne Loriot, Céline Narjoz, Céline Lambert, Bruno Pereira & Gisèle Pickering. (2019) Dextromethorphan and memantine after ketamine analgesia: a randomized control trial. Drug Design, Development and Therapy 13, pages 2677-2688.
Read now
Read now
Kinjal Patel, Petal S. Abdool, Tarek K. Rajji & Benoit H. Mulsant. (2017) Pharmacotherapy of major depression in late life: what is the role of new agents?. Expert Opinion on Pharmacotherapy 18:6, pages 599-609.
Read now
Read now
Nagendra S Singh, Carlos A Zarate$suffix/text()$suffix/text(), Ruin Moaddel, Michel Bernier & Irving W Wainer. (2014) What is hydroxynorketamine and what can it bring to neurotherapeutics?. Expert Review of Neurotherapeutics 14:11, pages 1239-1242.
Read now
Read now
Articles from other publishers (80)
Zack Blumenfeld, Kallol Bera, Eero Castrén & Henry A. Lester. (2023) Antidepressants enter cells, organelles, and membranes. Neuropsychopharmacology 49:1, pages 246-261.
Crossref
Crossref
Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, Ioline D. Henter & Carlos A. ZarateJrJr. (2023) Ketamine in neuropsychiatric disorders: an update. Neuropsychopharmacology 49:1, pages 23-40.
Crossref
Crossref
Mengfang Li, Qingqing Li, Dan Lin, Xiang Zheng, Lehao Jin, Jianping Cai, Guoxin Hu & Jianchang Qian. (2023) The variability in CYP3A4 activity determines the metabolic kinetic characteristics of ketamine. Toxicology 500, pages 153682.
Crossref
Crossref
Ruin Moaddel, Cristan A. Farmer, Mani Yavi, Bashkim Kadriu, Min Zhu, Jinshui Fan, Qinghua Chen, Elin Lehrmann, Giovanna Fantoni, Supriyo De, Caio H. Mazucanti, Elia E. Acevedo-Diaz, Peixiong Yuan, Todd D. Gould, Lawrence T. Park, Josephine M. Egan, Luigi Ferrucci & Carlos A. ZarateJr.Jr.. (2023) Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion. iScience 26:12, pages 108527.
Crossref
Crossref
Jenessa N. Johnston, Ioline D. Henter & Carlos A. ZarateJrJr. (2023) The antidepressant actions of ketamine and its enantiomers. Pharmacology & Therapeutics 246, pages 108431.
Crossref
Crossref
Ethan D. Angle & Philip M. Cox. (2023) Multidisciplinary Insights into the Structure–Function Relationship of the CYP2B6 Active Site. Drug Metabolism and Disposition 51:3, pages 369-384.
Crossref
Crossref
Nidhi Goswami, Mohd Aleem & Kailash Manda. (2022)
Intranasal (
2R, 6R
)‐hydroxynorketamine for acute pain: Behavioural and neurophysiological safety analysis in mice
. Clinical and Experimental Pharmacology and Physiology 50:2, pages 169-177.
Crossref
Crossref
Hidetoh Toki, Jun-ichi Yamaguchi, Akiko Mizuno-Yasuhira & Hiromi Endo. (2023) Chiral LC-MS/MS method for the simultaneous determination of (R,S)-ketamine, (R,S)-norketamine, and (2R,6R;2S,6S)-hydroxynorketamine in mouse plasma and brain. Journal of Pharmaceutical and Biomedical Analysis 224, pages 115168.
Crossref
Crossref
J. F. Nottage, A. Gabay, K. De Meyer, K. F. Herrik, J. F. Bastlund, S. R. Christensen, S. Gijsen & M. A. Mehta. (2022) The effect of ketamine and D-cycloserine on the high frequency resting EEG spectrum in humans. Psychopharmacology 240:1, pages 59-75.
Crossref
Crossref
Friederike A. Sandbaumhüter, Jordan T. Aerts, Regula Theurillat, Per E. Andrén, Wolfgang Thormann & Erik T. Jansson. (2022) Enantioselective CE–MS analysis of ketamine metabolites in urine. ELECTROPHORESIS 44:1-2, pages 125-134.
Crossref
Crossref
Romain Pelletier, Brendan Le Daré, Diane Le Bouëdec, Angéline Kernalléguen, Pierre-Jean Ferron, Isabelle Morel & Thomas Gicquel. (2022) Arylcyclohexylamine Derivatives: Pharmacokinetic, Pharmacodynamic, Clinical and Forensic Aspects. International Journal of Molecular Sciences 23:24, pages 15574.
Crossref
Crossref
Immaculate M. Langmia, Katja S. Just, Sabrina Yamoune, Julian Peter Müller & Julia C. Stingl. (2022) Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant ‐ implications for precision dosing in a global perspective. British Journal of Clinical Pharmacology 88:12, pages 5149-5165.
Crossref
Crossref
Jordi Bonaventura, Juan L. Gomez, Meghan L. Carlton, Sherry Lam, Marta Sanchez-Soto, Patrick J. Morris, Ruin Moaddel, Hye Jin Kang, Panos Zanos, Todd D. Gould, Craig J. Thomas, David R. Sibley, Carlos A. ZarateJr.Jr. & Michael Michaelides. (2022) Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search. Molecular Psychiatry 27:10, pages 4144-4156.
Crossref
Crossref
Mikołaj Matłoka, Sylwia Janowska, Anna Gajos-Draus, Hubert Ziółkowski, Monika Janicka, Przemysław Perko, Kisło Kamil, Piotr Pankiewicz, Rafał Moszczyński-Pętkowski, Mateusz Mach, Paulina Dera, Krzysztof Abramski, Małgorzata Teska-Kamińska, Ewa Tratkiewicz, Maciej Wieczorek & Jerzy Pieczykolan. (2022) Esketamine inhaled as dry powder: Pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study. Pulmonary Pharmacology & Therapeutics 73-74, pages 102127.
Crossref
Crossref
Thi Mai Loan Nguyen, Josephine Cecelia McGowan & Alain M. Gardier. (2022) CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity. Neuropharmacology 206, pages 108936.
Crossref
Crossref
Jaclyn N Highland, Cristan A Farmer, Panos Zanos, Jacqueline Lovett, Carlos A ZarateJr.Jr., Ruin Moaddel & Todd D Gould. (2021)
Sex-dependent metabolism of ketamine and (
2R,6R
)-hydroxynorketamine in mice and humans
. Journal of Psychopharmacology 36:2, pages 170-182.
Crossref
Crossref
Michael Weiss & Werner Siegmund. (2021) Pharmacokinetic Modeling of Ketamine Enantiomers and Their Metabolites After Administration of Prolonged‐Release Ketamine With Emphasis on 2,6‐Hydroxynorketamines. Clinical Pharmacology in Drug Development 11:2, pages 194-206.
Crossref
Crossref
Ethan Ponton, Gustavo Turecki & Corina Nagy. (2022) Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression. International Journal of Neuropsychopharmacology 25:1, pages 75-84.
Crossref
Crossref
Lena V. Danyeli, Florian N. Götting, Zümrüt Duygu Sen, Meng Li & Martin Walter. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
4593
4635
.
Thomas Gicquel, Romain Pelletier, Camille Richeval, Alexandr Gish, Florian Hakim, Pierre‐Jean Ferron, Vadim Mesli, Delphine Allorge, Isabelle Morel & Jean‐michel Gaulier. (2021)
Metabolite elucidation of 2‐fluoro‐deschloroketamine (2F‐DCK) using molecular networking across three complementary
in vitro
and
in vivo
models
. Drug Testing and Analysis 14:1, pages 144-153.
Crossref
Crossref
Michael Colla, Hanne Scheerer, Steffi Weidt, Erich Seifritz & Golo Kronenberg. (2021) Novel Insights Into the Neurobiology of the Antidepressant Response From Ketamine Research: A Mini Review. Frontiers in Behavioral Neuroscience 15.
Crossref
Crossref
Eric S. Schwenk, Marc C. Torjman, Ruin Moaddel, Jacqueline Lovett, Daniel Katz, William Denk, Clinton Lauritsen, Stephen D. Silberstein & Irving W. Wainer. (2021) Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis. The Journal of Clinical Pharmacology 61:11, pages 1421-1429.
Crossref
Crossref
Mahmoud Hasan, Christiane Modess, Tarek Roustom, Anne Dokter, Markus Grube, Andreas Link, Hélène Rey, Stefanie Adler, Konrad Meissner & Werner Siegmund. (2021) Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects. Anesthesiology 135:2, pages 326-339.
Crossref
Crossref
U. Joost Luelf, Guido J. Reiss, Ansgar Bokel & Vlada B. Urlacher. (2021)
Selective biocatalytic synthesis and crystal structure of (2
R
,6
R
)-hydroxyketaminium chloride, C
13
H
17
Cl
2
NO
2
. Zeitschrift für Kristallographie - New Crystal Structures 236:4, pages 827-829.
Crossref
Crossref
Immaculate M. Langmia, Katja S. Just, Sabrina Yamoune, Jürgen Brockmöller, Collen Masimirembwa & Julia C. Stingl. (2021) CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations—Implication for Drug Safety, Dosing, and Individualized Therapy. Frontiers in Genetics 12.
Crossref
Crossref
Yasushi Yamazoe & Masahiro Tohkin. (2021) Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template. Drug Metabolism and Pharmacokinetics 38, pages 100357.
Crossref
Crossref
Benjamin Sanders & Abdul Q. Brula. (2021) Intranasal esketamine: From origins to future implications in treatment-resistant depression. Journal of Psychiatric Research 137, pages 29-35.
Crossref
Crossref
Jaclyn N. Highland, Panos Zanos, Lace M. Riggs, Polymnia Georgiou, Sarah M. Clark, Patrick J. Morris, Ruin Moaddel, Craig J. Thomas, Carlos A. ZarateJr.Jr., Edna F. R. Pereira & Todd D. Gould. (2021) Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. Pharmacological Reviews 73:2, pages 763-791.
Crossref
Crossref
Luke A Jelen, Allan H Young & James M Stone. (2020) Ketamine: A tale of two enantiomers. Journal of Psychopharmacology 35:2, pages 109-123.
Crossref
Crossref
Shigeyuki Chaki & Jun-ichi Yamaguchi. 2021. The Neuroscience of Depression. The Neuroscience of Depression
381
391
.
Lena V. Danyeli, Florian N. Götting, Zümrüt Duygu Sen, Meng Li & Martin Walter. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
44
.
Lisa Kurzweil, Lena Danyeli, Zümrüt Duygu Şen, Anna Fejtova, Martin Walter & Sabrina Gensberger-Reigl. (2020) Targeted mass spectrometry of ketamine and its metabolites cis-6-hydroxynorketamine and norketamine in human blood serum. Journal of Chromatography B 1152, pages 122214.
Crossref
Crossref
Guido J. Reiss, Vlada B. Urlacher & U. Joost Luelf. (2020)
Enzyme-mediated synthesis and crystal structure of (2
R
,4
S
)-hydroxyketamine, C
13
H
16
ClNO
2
. Zeitschrift für Kristallographie - New Crystal Structures 235:5, pages 1037-1039.
Crossref
Crossref
Cristan A. Farmer, Jessica R. Gilbert, Ruin Moaddel, Jomy George, Lilian Adeojo, Jacqueline Lovett, Allison C. Nugent, Bashkim Kadriu, Peixiong Yuan, Todd D. Gould, Lawrence T. Park & Carlos A. ZarateJr.Jr.. (2020) Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology 45:8, pages 1398-1404.
Crossref
Crossref
F. Musshoff, G. Schwarz, H. Sachs, G. Skopp & T. Franz. (2020) Concentration distribution of more than 100 drugs and metabolites in forensic hair samples. International Journal of Legal Medicine 134:3, pages 989-995.
Crossref
Crossref
Ansgar Bokel, Ansgar Rühlmann, Michael C. Hutter & Vlada B. Urlacher. (2020)
Enzyme-Mediated Two-Step Regio- and Stereoselective Synthesis of Potential Rapid-Acting Antidepressant (2
S
,6
S
)-Hydroxynorketamine
. ACS Catalysis 10:7, pages 4151-4159.
Crossref
Crossref
Omar K. Sial, Eric M. Parise, Lyonna F. Parise, Tamara Gnecco & Carlos A. Bolaños-Guzmán. (2020) Ketamine: The final frontier or another depressing end?. Behavioural Brain Research 383, pages 112508.
Crossref
Crossref
Kateřina Hájková, Bronislav Jurásek, Jan Čejka, Kristýna Štefková, Tomáš Páleníček, David Sýkora & Martin Kuchař. (2020) Synthesis and identification of deschloroketamine metabolites in rats' urine and a quantification method for deschloroketamine and metabolites in rats' serum and brain tissue using liquid chromatography tandem mass spectrometry. Drug Testing and Analysis 12:3, pages 343-360.
Crossref
Crossref
Bernhard Luscher, Mengyang Feng & Sarah J. Jefferson. 2020. Rapid Acting Antidepressants. Rapid Acting Antidepressants
43
78
.
Christopher L. Shaffer, Jason K. Dutra, Wei Chou Tseng, Mark L. Weber, Luke J. Bogart, Katherine Hales, Jincheng Pang, Dmitri Volfson, Christopher W. am Ende, Michael E. Green & Derek L. Buhl. (2019) Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine. Neuropharmacology 153, pages 73-81.
Crossref
Crossref
Pan-Fen Wang, Alicia Neiner, Thomas R. Lane, Kimberley M. Zorn, Sean Ekins & Evan D. Kharasch. (2018) Halogen Substitution Influences Ketamine Metabolism by Cytochrome P450 2B6: In Vitro and Computational Approaches. Molecular Pharmaceutics 16:2, pages 898-906.
Crossref
Crossref
Jaclyn N Highland, Patrick J Morris, Panos Zanos, Jacqueline Lovett, Soumita Ghosh, Amy Q Wang, Carlos A ZarateJrJr, Craig J Thomas, Ruin Moaddel & Todd D Gould. (2018)
Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (
2R,6R
)-hydroxynorketamine
. Journal of Psychopharmacology 33:1, pages 12-24.
Crossref
Crossref
Kai Zhang, Hidetoh Toki, Yuko Fujita, Min Ma, Lijia Chang, Youge Qu, Shingo Harada, Tetsuhiro Nemoto, Akiko Mizuno-Yasuhira, Jun-ichi Yamaguchi, Shigeyuki Chaki & Kenji Hashimoto. (2018) Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model. Psychopharmacology 235:11, pages 3177-3185.
Crossref
Crossref
Pan-Fen WangAlicia NeinerEvan D. Kharasch. (2018) Stereoselective Ketamine Metabolism by Genetic Variants of Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase. Anesthesiology 129:4, pages 756-768.
Crossref
Crossref
Chun Yang, Shizuka Kobayashi, Kazuhito Nakao, Chao Dong, Mei Han, Youge Qu, Qian Ren, Ji-chun Zhang, Min Ma, Hidetoh Toki, Jun-ichi Yamaguchi, Shigeyuki Chaki, Yukihiko Shirayama, Kazu Nakazawa, Toshiya Manabe & Kenji Hashimoto. (2018) AMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine. Biological Psychiatry 84:8, pages 591-600.
Crossref
Crossref
Jun-ichi Yamaguchi, Hidetoh Toki, Youge Qu, Chun Yang, Hiroyuki Koike, Kenji Hashimoto, Akiko Mizuno-Yasuhira & Shigeyuki Chaki. (2018) (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice. Neuropsychopharmacology 43:9, pages 1900-1907.
Crossref
Crossref
Friederike A. Sandbaumhüter, Sara Vimercati, Wolfgang Thormann & Meike Mevissen. (2018) Role of the equine CYP3A94, CYP3A95 and CYP3A97 in ketamine metabolism in presence of medetomidine, diazepam and methadone studied by enantioselective capillary electrophoresis. Toxicology in Vitro 50, pages 242-248.
Crossref
Crossref
Panos Zanos, Ruin Moaddel, Patrick J. Morris, Lace M. Riggs, Jaclyn N. Highland, Polymnia Georgiou, Edna F. R. Pereira, Edson X. Albuquerque, Craig J. Thomas, Carlos A. ZarateJr.Jr. & Todd D. Gould. (2018) Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacological Reviews 70:3, pages 621-660.
Crossref
Crossref
Maria Amat-Foraster, Anders A. Jensen, Niels Plath, Kjartan F. Herrik, Pau Celada & Francesc Artigas. (2018) Temporally dissociable effects of ketamine on neuronal discharge and gamma oscillations in rat thalamo-cortical networks. Neuropharmacology 137, pages 13-23.
Crossref
Crossref
Ming-Fen Ho, Cristina Correia, James N. Ingle, Rima Kaddurah-Daouk, Liewei Wang, Scott H. Kaufmann & Richard M. Weinshilboum. (2018) Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. Biochemical Pharmacology 152, pages 279-292.
Crossref
Crossref
Tuomas O. Lilius, Hanna Viisanen, Viljami Jokinen, Mikko Niemi, Eija A. Kalso & Pekka V. Rauhala. (2018) Interactions of (2S,6S;2R,6R)-Hydroxynorketamine, a Secondary Metabolite of (R,S)-Ketamine, with Morphine. Basic & Clinical Pharmacology & Toxicology 122:5, pages 481-488.
Crossref
Crossref
Kai Zhang, Yuko Fujita & Kenji Hashimoto. (2018) Lack of metabolism in (R)-ketamine’s antidepressant actions in a chronic social defeat stress model. Scientific Reports 8:1.
Crossref
Crossref
Izumi Morita, Hiroyuki Oyama, Yui Kanda, Mayumi Yasuo, Aya Ito, Masahiro Toyota, Yoshinori Hayashi, Takeshi Yokoyama & Norihiro Kobayashi. (2018) Enantioselective Monoclonal Antibodies for Detecting Ketamine to Crack Down on Illicit Use. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 41:1, pages 123-131.
Crossref
Crossref
Yukihiko Shirayama & Kenji Hashimoto. (2018) Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine. International Journal of Neuropsychopharmacology 21:1, pages 84-88.
Crossref
Crossref
Gian Mario Mandolini, Matteo Lazzaretti, Alfredo Carlo Altamura & Paolo Brambilla. 2018. Hallucinations in Psychoses and Affective Disorders. Hallucinations in Psychoses and Affective Disorders
33
41
.
Friederike A. Sandbaumhüter, Regula Theurillat, Regula Bettschart-Wolfensberger & Wolfgang Thormann. (2017)
Effect of the α
2
-receptor agonists medetomidine, detomidine, xylazine, and romifidine on the ketamine metabolism in equines assessed with enantioselective capillary electrophoresis
. ELECTROPHORESIS 38:15, pages 1895-1904.
Crossref
Crossref
Friederike A. Sandbaumhüter, Regula Theurillat & Wolfgang Thormann. (2017) Separation of hydroxynorketamine stereoisomers using capillary electrophoresis with sulfated β-cyclodextrin and highly sulfated γ-cyclodextrin. ELECTROPHORESIS 38:15, pages 1878-1885.
Crossref
Crossref
Marshall W. Tyler, Harmony B. Yourish, Dawn F. Ionescu & Stephen J. Haggarty. (2017) Classics in Chemical Neuroscience: Ketamine. ACS Chemical Neuroscience 8:6, pages 1122-1134.
Crossref
Crossref
Todd D Gould, Panos Zanos & Carlos A ZarateJrJr. (2016) Ketamine Mechanism of Action: Separating the Wheat from the Chaff. Neuropsychopharmacology 42:1, pages 368-369.
Crossref
Crossref
Y.N. Martin & W.T. Nicholson. 2017. Essentials of Neuroanesthesia. Essentials of Neuroanesthesia
913
925
.
Janko Samardzic, Dubravka Svob Strac & John N. van den Anker. 2017. Total Intravenous Anesthesia and Target Controlled Infusions. Total Intravenous Anesthesia and Target Controlled Infusions
697
711
.
Lesley K. RaoAlicia M. FlakerChristina C. FriedelEvan D. Kharasch. (2016) Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance. Anesthesiology 125:6, pages 1103-1112.
Crossref
Crossref
Kai Yuan, Ying Han, Kenji Hashimoto & Lin Lu. (2016) On the Eve of Upgrading Antidepressants: (R)-Ketamine and Its Metabolites. Neuroscience Bulletin 32:6, pages 565-568.
Crossref
Crossref
Friederike A. Sandbaumhüter, Regula Theurillat, Rima N. Bektas, Annette P.N. Kutter, Regula Bettschart-Wolfensberger & Wolfgang Thormann. (2016) Pharmacokinetics of ketamine and three metabolites in Beagle dogs under sevoflurane vs. medetomidine comedication assessed by enantioselective capillary electrophoresis. Journal of Chromatography A 1467, pages 436-444.
Crossref
Crossref
A. Can, P. Zanos, R. Moaddel, H. J. Kang, K. S. S. Dossou, I. W. Wainer, J. F. Cheer, D. O. Frost, X.-P. Huang & T. D. Gould. (2016) Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters. Journal of Pharmacology and Experimental Therapeutics 359:1, pages 159-170.
Crossref
Crossref
R. Moaddel, M. Sanghvi, A. Ramamoorthy, K. Jozwiak, N. Singh, C. Green, K. O’Loughlin, M. Torjman & I.W. Wainer. (2016) Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats. Journal of Pharmaceutical and Biomedical Analysis 127, pages 3-8.
Crossref
Crossref
Panos Zanos, Ruin Moaddel, Patrick J. Morris, Polymnia Georgiou, Jonathan Fischell, Greg I. Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J. Pribut, Nagendra S. Singh, Katina S. S. Dossou, Yuhong Fang, Xi-Ping Huang, Cheryl L. Mayo, Irving W. Wainer, Edson X. Albuquerque, Scott M. Thompson, Craig J. Thomas, Carlos A. Zarate Jr & Todd D. Gould. (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533:7604, pages 481-486.
Crossref
Crossref
Regula Theurillat, Friederike A. Sandbaumhüter, Regula Bettschart-Wolfensberger & Wolfgang Thormann. (2016) Microassay for ketamine and metabolites in plasma and serum based on enantioselective capillary electrophoresis with highly sulfated γ-cyclodextrin and electrokinetic analyte injection. ELECTROPHORESIS 37:9, pages 1129-1138.
Crossref
Crossref
Nagendra S. Singh, Ewelina Rutkowska, Anita Plazinska, Mohammed Khadeer, Ruin Moaddel, Krzysztof Jozwiak, Michel Bernier & Irving W. Wainer. (2016) Ketamine Metabolites Enantioselectively Decrease Intracellular D-Serine Concentrations in PC-12 Cells. PLOS ONE 11:4, pages e0149499.
Crossref
Crossref
Michael W. Jann. 2016. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
579
601
.
Kinga Sałat, Agata Siwek, Gabriela Starowicz, Tadeusz Librowski, Gabriel Nowak, Urszula Drabik, Ryszard Gajdosz & Piotr Popik. (2015) Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor. Neuropharmacology 99, pages 301-307.
Crossref
Crossref
Friederike A. Sandbaumhüter, Regula Theurillat & Wolfgang Thormann. (2015)
Effects of medetomidine and its active enantiomer dexmedetomidine on
N
-demethylation of ketamine in canines determined
in vitro
using enantioselective capillary electrophoresis
. ELECTROPHORESIS 36:21-22, pages 2703-2712.
Crossref
Crossref
Shigeyuki Chaki & Kenichi Fukumoto. (2015) Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants. Pharmaceuticals 8:3, pages 590-606.
Crossref
Crossref
Nagendra S Singh, Michel Bernier, Simonetta Camandola, Mohammed A Khadeer, Ruin Moaddel, Mark P Mattson & Irving W Wainer. (2015)
Enantioselective inhibition of
d
-serine transport by (
S
)-ketamine
. British Journal of Pharmacology 172:18, pages 4546-4559.
Crossref
Crossref
Ruin Moaddel, Mitesh Sanghvi, Katina Sourou Sylvestre Dossou, Anuradha Ramamoorthy, Carol Green, James Bupp, Robert Swezey, Kathleen O'Loughlin & Irving W. Wainer. (2015) The distribution and clearance of (2S,6S)‐hydroxynorketamine, an active ketamine metabolite, in Wistar rats. Pharmacology Research & Perspectives 3:4.
Crossref
Crossref
Roman Řemínek, Zdeněk Glatz & Wolfgang Thormann. (2015) Optimized on-line enantioselective capillary electrophoretic method for kinetic and inhibition studies of drug metabolism mediated by cytochrome P450 enzymes. ELECTROPHORESIS 36:11-12, pages 1349-1357.
Crossref
Crossref
Raphaël Santamaria, Floriane Pailleux & Francis Beaudry. (2014)
In vitro
ketamine CYP3A-mediated metabolism study using mammalian liver S9 fractions, cDNA expressed enzymes and liquid chromatography tandem mass spectrometry
. Biomedical Chromatography 28:12, pages 1660-1669.
Crossref
Crossref
Rajib K. PaulNagendra S. SinghMohammed KhadeerRuin MoaddelMitesh SanghviCarol E. GreenKathleen O’LoughlinMarc C. TorjmanMichel BernierIrving W. Wainer. (2014)
(
R,S
)-Ketamine Metabolites (
R,S
)-norketamine and (
2S,6S
)-hydroxynorketamine Increase the Mammalian Target of Rapamycin Function
. Anesthesiology 121:1, pages 149-159.
Crossref
Crossref
Markus R. Meyer, Martina Bach, Jessica Welter, Michael Bovens, Alain Turcant & Hans H. Maurer. (2013) Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MS n. Analytical and Bioanalytical Chemistry 405:19, pages 6307-6321.
Crossref
Crossref
Ruin Moaddel, Galia Abdrakhmanova, Joanna Kozak, Krzysztof Jozwiak, Lawrence Toll, Lucita Jimenez, Avraham Rosenberg, Thao Tran, Yingxian Xiao, Carlos A. Zarate & Irving W. Wainer. (2013) Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. European Journal of Pharmacology 698:1-3, pages 228-234.
Crossref
Crossref